Prostaglandin D Synthase (Lipocalin)/PDS Antibody

About the Target

PGDS2 is a target of interest in many antibody-based workflows. Prostaglandin D Synthase (Lipocalin)/PDS, also known as β-trace protein, is a unique member of the lipocalin family that functions both as an enzyme and a transporter of lipophilic molecules. Structurally, it possesses the typical lipocalin β-barrel fold with a central hydrophobic cavity that accommodates diverse ligands, and it catalyzes the isomerization of prostaglandin H2 (PGH2) into prostaglandin D2 (PGD2) via its catalytic cysteine (Cys65). Depending on the literature source, PGDS2 may also be discussed as Prostaglandin D Synthase (Lipocalin)/PDS and PDS.

Reported cellular context includes cytoplasm, endoplasmic reticulum, golgi apparatus, and membrane, which can matter when signal is compared across treatments or changing cell states. Following PGDS2 across matched perturbations can help separate abundance effects from shifts in localization, complex assembly, or pathway state.

Research Context

PGDS2 is commonly interpreted in the context of inflammation, cardiovascular, and endocrinology research, and readouts are often stronger when a study separates expression changes from compartment-level redistribution. When reported signal spans cytoplasm, endoplasmic reticulum, and golgi apparatus, a defined reference condition can make comparisons more interpretable across perturbations, passages, or replicate sets.

Consider these angles when interpreting target-level changes:

• apparent redistribution between cytoplasm, endoplasmic reticulum, and golgi apparatus across matched conditions
• responses associated with cytokine exposure, inflammatory tone, or tissue stress
• changes linked to vascular, contractile, or hemodynamic cell-state cues
• responses to hormone-dependent signaling or endocrine feedback context

Variant Considerations

If your project spans exploratory questions, the regular version offers a balanced option for establishing baseline signal behavior for PGDS2. This can help when protocols evolve over time and the goal is to compare experiments using a stable reference workflow.

Standardize sampling time, control choice, and downstream analysis thresholds so apparent differences in PGDS2 reflect biology rather than handling. When interpreting PGDS2, it is often useful to decide early whether the main question is overall abundance, compartmental enrichment, or context-dependent redistribution.

For multi-run studies, a shared reference condition can keep PGDS2 trends easier to compare across datasets. That kind of consistency is especially helpful when follow-up work expands to new perturbations, model systems, or longitudinal collections.